Akebia Therapeutics, Inc. (AKBA) Social Stream

Featured Post From StockTwits About AKBA

Will post Telegram to join my team once posts complete, follow and don’t miss out! Have a blessed weekend!

$AKBA
Market Price - $2.56
Average Hold - $3.40
Accumulate - Sub $2.45 (raised from $2.30)
Price Target - $5
Estimated Time Hold - 2Q
Support - $2.75, $3.40
Floor - $2.09
Double Down Target - Sub $2
Option - N/A
Micro DD - In March, Akebia submitted an NDA to the FDA for vadadustat for the treatment of anemia due to CKD in both adult patients on dialysis and adult patients not on dialysis. In late May, the FDA accepted for filing the NDA for vadadustat for the treatment of anemia due to CKD in both adult patients on dialysis and adult patients not on dialysis. The FDA assigned the application a standard review and a PDUFA target action date of March 29, 2022. Cash, cash equivalents and available-for-sale securities as of June 30, 2021 were $247.0 million .